Valvular Heart Disease Registry Focusing on Gender Differences
Valvular Heart Disease in Women Registry
This registry will track care and outcomes for adults with valvular heart disease to see if there are gender differences from hospital admission through the first outpatient follow-up.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Valvular Heart Disease in Women Registry Research network |
| Locations | 2 sites (Aswān and 1 other locations) |
| Trial ID | NCT07196930 on ClinicalTrials.gov |
What this trial studies
This is a multicenter observational registry that will enroll adults admitted with any valvular heart disease as defined by current ESC guidelines and collect clinical, diagnostic, treatment, and follow-up data. Data will be gathered from the point of hospital admission (elective or urgent) through the first outpatient clinic visit to capture pathways of care and guideline adherence. The registry will analyze differences by gender in diagnosis, use of therapies, and early outcomes, without altering patient care. The European Association of Cardiovascular Imaging is a listed collaborator, and participating sites include centers such as Aswan Heart Centre and the University of Lisbon.
Who should consider this trial
Good fit: Adults aged 18 years or older with any valvular heart disease per current ESC guidelines who are admitted to a participating registry center and can provide informed consent are eligible.
Not a fit: People under 18, those unable to give informed consent, and patients not treated at participating centers are not eligible and are unlikely to receive direct benefit from this registry.
Why it matters
Potential benefit: If successful, the registry could identify gaps in diagnosis and treatment that lead to more equitable, guideline-based care for patients with valvular heart disease.
How similar studies have performed: Previous valvular heart disease registries and cardiovascular databases have documented gender-based gaps in care, though dedicated multinational registries focused on women remain relatively limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients with diagnosis of any VHD according to the current ESC guidelines. * Admission to the VHD-W Registry collaborating center. Exclusion Criteria: * Age less than 18 years old. * Inability to provide informed consent per local institutional and regulatory requirements.
Where this trial is running
Aswān and 1 other locations
- Aswan Heart Centre — Aswān, Egypt (Recruiting)
- University of Lisbon — Lisbon, Portugal (Recruiting)
Study contacts
- Principal investigator: Julia Grapsa, MD PhD — Harvard Medical School (HMS and HSDM)
- Study coordinator: Shehab Anwer, MD
- Email: shehab.anwer@gmail.com
- Phone: +41788816333
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.